Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases, has announced its participation in two major investor conferences this November. Natalie Holles, CEO, will present at the Stifel 2024 Healthcare Conference on November 19 at 3:00 p.m. EST, while Chris Murphy, CFO, will speak at the Jefferies London Healthcare Conference on the same day at 11:00 a.m. GMT. Live audio webcasts will be available on Third Harmonic's website, with replays accessible for 90 days after the events.
Third Harmonic Bio (Nasdaq: THRD), un'azienda biofarmaceutica in fase clinica che sviluppa trattamenti per le malattie infiammatorie, ha annunciato la sua partecipazione a due importanti conferenze per investitori questo novembre. Natalie Holles, CEO, presenterà alla Stifel 2024 Healthcare Conference il 19 novembre alle 15:00 EST, mentre Chris Murphy, CFO, interverrà alla Jefferies London Healthcare Conference lo stesso giorno alle 11:00 GMT. Saranno disponibili webcast audio dal vivo sul sito web di Third Harmonic, con la possibilità di rivedere le registrazioni per 90 giorni dopo gli eventi.
Third Harmonic Bio (Nasdaq: THRD), una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos para enfermedades inflamatorias, ha anunciado su participación en dos importantes conferencias para inversores este noviembre. Natalie Holles, CEO, presentará en la Stifel 2024 Healthcare Conference el 19 de noviembre a las 3:00 p.m. EST, mientras que Chris Murphy, CFO, hablará en la Jefferies London Healthcare Conference el mismo día a las 11:00 a.m. GMT. Se dispondrá de webcasts de audio en vivo en el sitio web de Third Harmonic, con repeticiones accesibles durante 90 días después de los eventos.
Third Harmonic Bio (Nasdaq: THRD)는 염증 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, 이번 11월 두 개의 주요 투자자 회의에 참석한다고 발표했습니다. Natalie Holles CEO는 11월 19일 오후 3시 EST에 Stifel 2024 Healthcare Conference에서 발표할 예정이며, Chris Murphy CFO는 같은 날 오전 11시 GMT에 Jefferies London Healthcare Conference에서 연설할 예정입니다. Third Harmonic 웹사이트에서 실시간 오디오 웹캐스트가 제공되며, 이벤트 종료 후 90일 동안 다시 시청할 수 있습니다.
Third Harmonic Bio (Nasdaq: THRD), une entreprise biopharmaceutique en phase clinique développant des traitements pour les maladies inflammatoires, a annoncé sa participation à deux grandes conférences d'investisseurs ce mois de novembre. Natalie Holles, PDG, fera une présentation lors de la Stifel 2024 Healthcare Conference le 19 novembre à 15h00 EST, tandis que Chris Murphy, CFO, prendra la parole à la Jefferies London Healthcare Conference le même jour à 11h00 GMT. Des webcasts audio en direct seront disponibles sur le site Web de Third Harmonic, avec des rediffusions accessibles pendant 90 jours après les événements.
Third Harmonic Bio (Nasdaq: THRD), ein biopharmazeutisches Unternehmen in klinischer Entwicklung, das Behandlungen für entzündliche Erkrankungen entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im November bekannt gegeben. Natalie Holles, CEO, wird am 19. November um 15:00 Uhr EST auf der Stifel 2024 Healthcare Conference präsentieren, während Chris Murphy, CFO, am selben Tag um 11:00 Uhr GMT auf der Jefferies London Healthcare Conference sprechen wird. Live-Audio-Webcasts werden auf der Website von Third Harmonic verfügbar sein, mit Wiederholungen, die 90 Tage nach den Veranstaltungen zugänglich sind.
- None.
- None.
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences:
- Natalie Holles, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 3:00 p.m. EST
- Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:00 a.m. GMT / 6:00 a.m. EST
A live audio webcast of each fireside chat will be available within the Investors & Media section of the Third Harmonic Bio website. Archived replays will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
When is Third Harmonic Bio (THRD) presenting at the Stifel Healthcare Conference 2024?
What time is Third Harmonic Bio's (THRD) presentation at the Jefferies London Healthcare Conference?
How long will Third Harmonic Bio's (THRD) November 2024 conference webcasts be available?
